• In individuals with ongoing viraemia and with few options to construct a fully suppressive regimen, referral for specialist advice and/or discussion in a multidisciplinary team ‘virtual’ clinic is imperative.
  • In those with significant resistance, include at least two and preferably three fully active agents with at least one active PI/r (preferably DRV/r) and one agent with a novel mechanism of action (preferably intergrase inhibitor, or CCR5 antagonist or fusion inhibitor).
  • Treatment interruption is not recommended.